Another study identified the oncogenic UBE2L3-KRAS fusion in DU145 prostate cancer cells using an integrative genomics approach, and further investigation demonstrated that the fusion of UBE2L3 with KRAS may lead to the progression of metastases in rare subsets of prostate cancer (140). The gene discussed is KRAS; the disease is prostate carcinoma.